Merck presents results from head-to-head Phase 3 KEYNOTE-598 Trial evaluating KEYTRUDA® (pembrolizumab) in combination with ipilimumab versus KEYTRUDA Monotherapy in certain patients with metastatic non-small cell lung cancer
Findings Presented in World Conference on Lung Cancer 2020 Presidential Symposium and Published in the Journal of Clinical Oncology KENILWORTH, N.J. — (BUSINESS WIRE) — $MRK #MRK— Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time data